New Directions for Scleroderma Treatments, with Dr. Andrew Tager (2013)

Dr. Andrew Tager focuses his research efforts on understanding the mechanisms that cause two fibrotic diseases, scleroderma and idiopathic pulmonary fibrosis (IPF). Fibrosis, or scarring, in these diseases remains an unmet need that causes high morbidity and mortality, and is largely unresponsive to currently available pharmacologic therapies.

Dr. Tager’s lab is focused on identifying chemicals produced by the body that promote the development of fibrosis. Most importantly, his work aims to find ways to inhibit such molecules to prevent the progression of fibrotic diseases, and/or promote healing of scarred organs.

With clinical trials currently planned that target a chemical promoting fibrosis in scleroderma skin and IPF, Dr. Tager is uniquely qualified to present on new directions for scleroderma treatments and understanding the basis for current clinical trials.